Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Chronic Bronchiolitis or Resistant Asthma?

This study has been completed.
Sponsor:
Information provided by:
Baqiyatallah Medical Sciences University
ClinicalTrials.gov Identifier:
NCT00368342
First received: August 22, 2006
Last updated: February 17, 2009
Last verified: January 2006
  Purpose

Chronic Bronchiolitis or Resistant Asthma? Testing a way to diagnosis and treatment


Condition Intervention Phase
Asthma
Drug: Erythromycin, Azithromycin , Clarithromycin
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Baqiyatallah Medical Sciences University:

  Eligibility

Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Difficult asthma

Exclusion Criteria:

  • Patients with potential allergic bronchopulmonary aspergillosis i.e. with peripheral blood eosinophilia, sputum eosinophilia, or any sputum production and bronchiectasis
  • A history of smoking
  • Significant occupational or environmental exposures
  • Evidence on emphysema on chest high resolution computed tomography (HRCT) scan
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00368342

Sponsors and Collaborators
Baqiyatallah Medical Sciences University
Investigators
Principal Investigator: Mostafa Ghanei, Prof Research Center of Chemical Injuries, Baqyatallah Medical Sciences University, Tehran, Iran
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00368342     History of Changes
Other Study ID Numbers: S-340-14-6-1-PU-79
Study First Received: August 22, 2006
Last Updated: February 17, 2009
Health Authority: Iran: Ethics Committee

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases
Clarithromycin
Erythromycin
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Synthesis Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014